Dapaconazole - Biolab Sanus Farmaceutica
Alternative Names: BL-123; BL-125; ZiltLatest Information Update: 11 Oct 2021
Price :
$50 *
At a glance
- Originator Biolab Sanus Farmaceutica
- Class Antifungals; Chlorophenols; Imidazoles; Small molecules
- Mechanism of Action 14-alpha demethylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Tinea pedis
- No development reported Tinea cruris
Most Recent Events
- 11 Oct 2021 Phase-III development is ongoing for Tinea pedis in Brazil (NCT03320486)
- 11 Oct 2021 No development reported - Phase-II for Tinea cruris in Brazil (Topical) (CT03359070)
- 12 Nov 2019 Biolab Sanus Farmaceutica comletes a phase III trial for Tinea pedis in Brazil (Topical) (NCT03320486)